Form 4: Director Kerry Hicks Increases Stake in TriSalus Life
Director Equity Grant Disclosure
Director Kerry R. Hicks acquired 28,201 restricted stock units and 56,403 stock options in TriSalus Life Sciences, Inc.
Summary
- Director Kerry R. Hicks received a grant of 28,201 restricted stock units (RSUs) on May 14, 2026.
- The director also received a grant of 56,403 stock options with an exercise price of $2.52 per share.
- Both the RSU award and the stock options are scheduled to vest fully on the one-year anniversary of the grant date, May 14, 2027.
- Following these transactions, the director's direct beneficial ownership of common stock increased to 542,790 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine disclosure of director compensation, which is neutral in terms of immediate market impact.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
- Retention of key leadership through one-year cliff vesting schedules.
Negatives
- Potential for future dilution of existing shareholders upon the exercise of options and vesting of RSUs.
Risks
- Continued service requirement for vesting creates dependency on the director's ongoing tenure.
- Market price volatility may impact the future value of the granted equity.
Future Outlook
The equity grants are subject to continued service, with full vesting occurring on May 14, 2027.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure long-term alignment between board members and shareholders.
Comparison to Industry Standards
- The use of one-year cliff vesting for director equity is consistent with standard practices for small-cap life sciences companies.
- The exercise price of $2.52 reflects the current market valuation of the issuer's common stock.
Related Party Transactions
- The director maintains indirect ownership through HW Investment Partners, LLC, The Kerry Raymond Hicks Dynasty Trust, and Millennium Trust Company, LLC.
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual exercise or vesting of these equity instruments.
Next Steps
- Vesting of RSU and option awards on May 14, 2027.
Key Dates
| Date | Description |
|---|---|
| 05/14/2026 | Date of grant for RSUs and stock options. |
| 05/15/2026 | Date of filing. |
| 05/13/2036 | Expiration date for the granted stock options. |
Keywords
TriSalus Life Sciences, TLSI, Form 4, Insider Trading, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.